New 1,3,4-thiadiazole derivatives as inhibitors of critical steps of the glutamine-glutamate cycle in glioblastoma cells.
2013/11/D/NZ7/00925
Keywords
Descriptors
- NZ7_14: Farmacja, farmakoterapia, farmakologia
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN
Voivodeship: mazowieckie
Principal investigator (from the host institution)
dr hab. Monika Paulina Szeliga
Number of co-investigators in the project: 3
Call
SONATA 6 – announced on 2013-09-16
- Amount awarded
- 435 500 PLN
- Project start date
- 2014-07-10
- Project end date
- 2018-01-09
- Project duration
- 42 months (the same as in the proposal)
- Project status
- Project settled
Information in the final report
Publication in academic press/journals (2)
-
Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status.
- Authors:
- Szeliga M, Bogacińska-Karaś M, Kuźmicz K, Rola R, Albrecht J.
- Academic press:
- Molecular Carcinogenesis (year: 2016, volume: 55(9), pages: 1309-1316), Publisher: Wiley Periodicals, Inc.
- Status:
- Published
- DOI:
- 10.1002/mc.22372 – link to the publication
-
Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway.
- Authors:
- Majewska E, Márquez J, Albrecht J, Szeliga M.
- Academic press:
- Cansers (Basel) (year: 2019, volume: 11, pages: pii: E115), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/cancers11010115. – link to the publication